Nausea, vomiting, constipation, and reduced appetite are common during dose escalation and typically improve within 12 weeks at each new dose
NCT01620255
Insuficiencia heptica ZINC SULFATO Insuficiencia renal ZINC SULFATO Precaucin en I.R
Other ingredients Purified water, phosphoric acid, natural flavors, stevia leaf extract, potassium sorbate, sodium benzoate
Featured Image: Patrick Bay Damsted on Adobe Stock Author:
SPL UNCLASSIFIED SECTION Never Share a MOUNJARO KwikPen Between Patients Advise patients that they must never share a MOUNJARO KwikPen with another person, even if the pen needle is changed, because doing so carries a risk for transmission of blood-borne pathogens [see Warnings and Precautions (5.10)]